The successful transition from limited to full market release suggests strong product-market fit. Traders should monitor upcoming revenue guidance and adoption rates in new territories as indicators of commercial success.
Price Chart
Executive Summary
Microbot Medical announced the successful limited market release and commencement of full market release for its LIBERTY Endovascular Robotic System in the U.S., with adoption by major healthcare systems including Emory Healthcare and Tampa General Hospital. The company has expanded its commercial team from four to eight sales territories in preparation for the full rollout.
Key Facts
- Microbot Medical has successfully executed the limited market release of its LIBERTY Endovascular Robotic System
- The company is commencing full market release in the U.S. at the Society of Interventional Radiology Annual Scientific Meeting
- LIBERTY has been adopted by multiple healthcare systems including Emory Healthcare and Tampa General Hospital
- The system has been used commercially across various procedures including Prostate Artery Embolization, Uterine Fibroid Embolization, and Y90 deliveries
- Company has expanded commercial team from four to eight sales territories, with goal of 12 territories by end of 2026
Financial Impact
Potential significant revenue growth from commercialization of LIBERTY system
Risk Factors
- Execution risk in scaling commercial operations nationwide
- Competition from established players in robotic surgery space
- Regulatory challenges for new medical device approvals
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001493152-26-016293 |
| Exhibit: ex99-1.htm | 0001493152-26-016293 |
| Document: 0001493152-26-016293-index-headers.html | 0001493152-26-016293 |
| Document: 0001493152-26-016293-index.html | 0001493152-26-016293 |
| Document: 0001493152-26-016293.txt | 0001493152-26-016293 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 23, 2026 3d ago | 8-K | $0.9799 | awaiting T+1 | — | $0.9700 (−1.01%) |
Oct 20, 2026 6d ago | 8-K | $0.9475 $0.9401 | ▼ −0.78% | ▼ −1.31% | $0.9700 (+2.37%) |
Oct 6, 2026 20d ago | 8-K | $1.07 $1.12 | ▲ +4.67% | ▲ +4.91% | $0.9700 (−9.35%) |
Oct 6, 2026 20d ago | Press Release | $1.07 $1.12 | ▲ +4.67% | ▲ +4.91% | $0.9700 (−9.35%) |
Sep 28, 2026 28d ago | 8-K | $1.25 $1.25 | ▼ −0.40% | ▼ −0.22% | $0.9700 (−22.40%) |
Aug 11, 2026 10w ago | 8-K | $1.68 $1.74 | ▲ +3.27% | ▲ +3.02% | $0.9700 (−42.26%) |
Jul 21, 2026 13w ago | 8-K | $1.80 $1.77 | ▼ −1.67% | ▼ −1.55% | $0.9700 (−46.11%) |
Jul 7, 2026 15w ago | 8-K | $1.90 $1.87 | ▼ −1.58% | ▼ −1.27% | $0.9700 (−48.95%) |
Jun 30, 2026 16w ago | 8-K | $1.95 $1.91 | ▼ −2.05% | ▼ −1.92% | $0.9700 (−50.26%) |
Jun 16, 2026 18w ago | 8-K | $1.82 $1.88 | ▲ +3.30% | ▲ +4.55% | $0.9700 (−46.70%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers